Tianjin Lisheng Pharmaceutical (SHE:002393) reported a net profit attributable to owners of 184.5 million yuan for the year 2024, down from 361.8 million yuan in the prior year.
Earnings per share fell to 0.72 yuan from 1.40 yuan a year ago, its parent company Tianjin Development Holdings (HKG:0882) said in a Friday filing with the Hong Kong bourse.
Total operating income, however, rose to 1.34 billion yuan from 1.15 billion yuan in the previous year.
The company proposed a 0.35 yuan per-share dividend, inclusive of taxes. The dividend is subject to approval by the shareholders.
Tianjin Lisheng's shares fell 3% in Shenzhen.
Price (HKD): $17.83, Change: $+0.15, Percent Change: +0.85%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。